Engineered Gut Bacteria Shows Promise in Phase 1/2a Trial for Kidney Stone Prevention
核心洞察
Stanford University researchers successfully engineered gut bacteria to break down oxalate (搜索), a key component in kidney stone formation, demonstrating reduced oxalate levels in both animal models and human clinical trials.
The phase 1/2a trial involving 51 participants showed that all individuals receiving the engineered bacteria had lower oxalate (搜索) levels compared to the placebo group after one month of treatment.
The engineered bacteria utilizes porphyran (搜索), a seaweed-derived nutrient rarely used by Western gut microbiomes, creating a controllable therapeutic niche with a built-in "kill switch" mechanism.
Stanford University researchers have achieved a significant breakthrough in kidney stone prevention by successfully engineering gut bacteria to target oxalate (搜索), the primary culprit behind recurrent kidney stones (搜索). The phase 1/2a clinical trial, published in the journal Science, demonstrates the first successful application of engineered microbiome therapy for this condition.
Novel Bacterial Engineering Approach
The research team, led by Dr. Weston Whitaker, a microbiologist at Stanford University, genetically modified Phocaeicola vulgatus (搜索), a common gut bacterium, to break down oxalate (搜索)—a substance found in foods like spinach, nuts, dark chocolate, and tea that can bind with calcium to form kidney stones (搜索). The engineered bacteria was designed to consume porphyran (搜索), a carbohydrate derived from red seaweed that most gut bacteria cannot digest.
"The bacteria was tweaked so that it broke down the oxalate (搜索) and fed off a type of carbohydrate (porphyran (搜索), found in red seaweed) that most gut bacteria can't digest, so enabling it to survive among the resident bugs," Dr. Whitaker explained. This approach creates an unoccupied ecological niche, as only about 2% of Western populations naturally carry bacteria with porphyran-metabolizing capability.
Clinical Trial Results
The trial enrolled 51 participants, including 12 individuals with enteric hyperoxaluria (搜索)—a condition where the body absorbs excessive oxalate (搜索), leading to frequent kidney stones (搜索)—and 39 healthy volunteers. Participants received either the engineered bacteria pill or a placebo daily for one month, along with porphyran (搜索) powder mixed with water and a proton pump inhibitor to protect the bacteria from stomach acid.
After one month of treatment, all participants who received the engineered bacteria showed lower oxalate (搜索) levels compared to the placebo group. The therapeutic approach includes a built-in safety mechanism that Dr. Whitaker describes as a "kill switch"—the bacteria can be cleared from the system simply by stopping the daily porphyran (搜索) powder.
Addressing Current Treatment Limitations
According to NHS data, approximately half of all people who develop kidney stones (搜索) will experience recurrence within five years. Professor Chris Eden, a consultant urologist at the Royal Surrey County Hospital, noted that current treatments depend on stone location, size, and symptoms. "Larger stones within the kidney typically cause symptoms [pain and/or recurrent infection] and can be broken with external shockwave lithotripsy [a form of ultrasound], but the fragments then have to pass," he explained.
Professor Eden welcomed the research while acknowledging its early stage, stating: "Potentially, this may be useful for the subset of patients with recurrent oxalate (搜索) kidney stones (搜索) who don't respond to a low-oxalate diet."
Challenges and Future Directions
Despite the promising results, the study revealed several challenges that need addressing before clinical implementation. Dr. David Riglar, an assistant professor of engineering biology at Imperial College London, emphasized the importance of the research while noting concerns: "There are many unknowns about how our gut bacteria interact with our bodies, which raises some challenges for microbiome engineering."
Key challenges identified include persistent bacterial colonization in some participants even after removing the porphyran (搜索) food source, and horizontal gene transfer events that could compromise the strain's therapeutic function. The researchers also noted issues with strain stability and competition from native microbes.
Broader Therapeutic Applications
The Stanford team believes this approach could extend beyond kidney stones (搜索). Dr. Whitaker suggests that genetically altering gut bacteria could be used to "treat or prevent a wide range of gut and non gut-related diseases." The team is already testing the approach for irritable bowel syndrome (搜索) (IBS).
Meanwhile, researchers at Imperial College London are investigating how bacteria behave differently in inflamed gut areas, such as in inflammatory bowel disease (搜索) (IBD) or near tumors. "Our goal is to design engineered probiotics [beneficial bacteria] that can diagnose and treat these gut problems on site – but only when required," Dr. Riglar explained.
Next Steps
Further research is planned to extend the duration of bacterial effectiveness and develop long-term preventative approaches. The study represents a crucial step forward in microbiome engineering, demonstrating that engineered gut bacteria can safely colonize the human gut and deliver therapeutic effects, while highlighting the complexities that remain to be solved in this emerging field.